ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

23-Nov-2020

Outsourcing-Pharma.com provided the following news item; "The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidate's potential in overcoming resistance of a cancer drug."

Click here to read more

16-Nov-2020

TrialSite News, the digital media news site dedicated to coverage of clinical research trials, reported the following, “Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda®, to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo®) in the treatment of cancer.”

Click here to read more

13-Nov-2020

Australian stock market digital news site, The Market Herald, reported "Major breakthrough validates Noxopharm's(ASX:NOX) cancer therapy", following the November 13, 2020 ASX announcement regarding independent Weill Cornell Medical College research.

Click here to read more

13-Nov-2020

Investing.com(AU) mentioned in a Brief: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more

13-Nov-2020

Yahoo!Finance noted Noxopharm’s (ASX:NOX) announcement regarding the planned pilot study with Bristol Myers Squibb (BMS) using NOX’s lead drug candidate, Veyonda, and the BMS drug, Opdivo.

Click here to read more

12-Nov-2020

MarketWatch news site noted Noxopharm’s pilot study in cancer patients with Bristol Myers Squibb;

Click here to read more

Note: MarketWatch News Department was not involved in the creation of this content


12-Nov-2020

Digital stock market news site, TD Ameritrade posted: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more

12-Nov-2020

BioSpace, the Life Science industry digital news and information source reported, “Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product”

Click here to read more

12-Nov-2020

BioWorld, in its Other News to Note section said,” Noxopharm Ltd., of Sydney, is partnering with Bristol Myers Squibb Co., of New York, to study Noxopharm's sphingosine-1-phosphate inhibitor, Veyonda, in cancer patients who have developed a resistance to BMS’ Opdivo (nivolumab). The study, called Iconic-1, will start recruiting patients early in 2021.”

Click here to read more

12-Nov-2020

In relation to Noxopharm’s announcement, a digital news site to the pharmaceutical industry, FirstWord Pharma, reported the following

Click here to read more